Surrozen, Inc. (SRZN)
31.73
-0.25
(-0.78%)
USD |
NASDAQ |
Sep 30, 10:53
Surrozen Enterprise Value : 280.17M for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 280.17M |
| September 28, 2026 | 252.67M |
| September 25, 2026 | 251.49M |
| September 24, 2026 | 300.15M |
| September 23, 2026 | 94.22M |
| September 22, 2026 | 111.15M |
| September 21, 2026 | 98.57M |
| September 18, 2026 | 98.81M |
| September 17, 2026 | 103.39M |
| September 16, 2026 | 103.27M |
| September 15, 2026 | 113.15M |
| September 14, 2026 | 113.97M |
| September 11, 2026 | 127.60M |
| September 10, 2026 | 132.89M |
| September 09, 2026 | 139.71M |
| September 08, 2026 | 147.35M |
| September 04, 2026 | 171.80M |
| September 03, 2026 | 169.21M |
| September 02, 2026 | 169.92M |
| September 01, 2026 | 165.22M |
| August 31, 2026 | 163.10M |
| August 28, 2026 | 167.80M |
| August 27, 2026 | 186.49M |
| August 26, 2026 | 182.96M |
| August 25, 2026 | 178.85M |
| Date | Value |
|---|---|
| August 24, 2026 | 186.02M |
| August 21, 2026 | 186.26M |
| August 20, 2026 | 180.50M |
| August 19, 2026 | 186.49M |
| August 18, 2026 | 186.37M |
| August 17, 2026 | 183.79M |
| August 14, 2026 | 185.90M |
| August 13, 2026 | 183.20M |
| August 12, 2026 | 188.61M |
| August 11, 2026 | 198.71M |
| August 10, 2026 | 199.18M |
| August 07, 2026 | 205.41M |
| August 06, 2026 | 158.63M |
| August 05, 2026 | 162.28M |
| August 04, 2026 | 162.86M |
| August 03, 2026 | 160.28M |
| July 31, 2026 | 165.33M |
| July 30, 2026 | 149.11M |
| July 29, 2026 | 129.95M |
| July 28, 2026 | 132.30M |
| July 27, 2026 | 137.12M |
| July 24, 2026 | 136.18M |
| July 23, 2026 | 152.99M |
| July 22, 2026 | 159.57M |
| July 21, 2026 | 174.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.125B |
| Oncolytics Biotech, Inc. | 80.40M |
| Sangamo Therapeutics, Inc. | 49.74M |
| Sarepta Therapeutics, Inc. | 2.226B |
| Anixa Biosciences, Inc. | 83.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 32.04M |
| Revenue (Quarterly) | 5.00M |
| Total Expenses (Quarterly) | -27.04M |
| EPS Diluted (Quarterly) | -0.4059 |
| Gross Profit Margin (Quarterly) | 98.98% |
| Earnings Yield | -139.6% |
| Normalized Earnings Yield | -78.22 |